Ocumension Therapeutics
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical company focused on the identification, development, and commercialization of innovative therapies for eye diseases. The company aims to address significant unmet medical needs in the ophthalmic field by providing comprehensive pharmaceutical solutions. Its extensive portfolio includes various product candidates such as OT-401, OT-101, OT-301, OT-1001, OT-502, OT-202, OT-503, and several others. Ocumension Therapeutics has established a platform that integrates specialized capabilities across the entire development cycle of ophthalmic drugs, encompassing research, manufacturing, and commercialization. This strategic approach positions the company to potentially lead the ophthalmology market in China, leveraging its first-mover advantage to enhance patient care.
Alimera Sciences is a pharmaceutical company focused on the research, development, and commercialization of prescription ophthalmic pharmaceuticals, particularly for diseases affecting the retina. The company’s primary product, ILUVIEN, is an intravitreal implant designed to treat diabetic macular edema (DME), a condition that poses a significant risk of vision loss in diabetic patients. ILUVIEN provides sustained release of the corticosteroid fluocinolone acetonide through a non-surgical procedure, allowing for a self-sealing wound. In addition to DME, the company also targets non-infectious uveitis affecting the posterior segment of the eye. Alimera operates in various international markets, including the United States, Germany, the United Kingdom, China, and the Middle East, utilizing both direct sales and distribution channels to reach physician offices, pharmacies, and hospitals. Founded in 2003 and headquartered in Alpharetta, Georgia, Alimera Sciences is dedicated to improving retinal health and vision preservation through innovative treatments.
EyePoint Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing ophthalmic products for the treatment of eye diseases, primarily in the United States and Europe. The company offers several FDA-approved products, including ILUVIEN for diabetic macular edema, YUTIQ for chronic non-infectious uveitis, DEXYCU for post-operative ocular inflammation, and Retisert for posterior segment uveitis. EyePoint is also advancing its pipeline with EYP-1901, a bioerodible implant targeting wet age-related macular degeneration and related conditions, as well as YUTIQ50 for uveitis. The company utilizes its proprietary Durasert and Verisome technology platforms to create sustained-release drug delivery systems. EyePoint has established strategic collaborations with various organizations and engages in a commercial alliance for the promotion of its products. Founded in 1987 and headquartered in Watertown, Massachusetts, EyePoint was previously known as pSivida Corp.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.